论文部分内容阅读
目的:探讨中晚期肝癌肝动脉化疗栓塞的疗效及影响疗效的因素。方法:对38例不能切除的原发性肝癌行选择性肝动脉插管灌注化疗。结果:选择性肝动脉插管灌注化疗栓塞0·5、1和2年生存率分别为60·5%(23/38)、26·3%(10/38)和0·3%(1/38),平均生存期为7·9个月。肿块类型与大小、栓塞剂及用量和甲胎蛋白的变化是影响疗效的主要因素。结论:选择性肝动脉插管灌注化疗栓塞可作为中晚期肝癌的常规治疗方法。
Objective: To investigate the curative effect of transcatheter arterial chemoembolization in advanced hepatocellular carcinoma and its influencing factors. Methods: Thirty-eight cases of unresectable primary liver cancer underwent selective hepatic arterial infusion chemotherapy. Results: The 0.5, 1, 2 year survival rates of selective hepatic artery catheterization and chemoembolization were 60.5% (23/38), 26.3% (10/38) and 0.3% (1 / 38), with an average survival of 7.9 months. The type and size of the tumor, the amount of embolic agent and dosage and the change of alpha-fetoprotein are the main factors affecting the curative effect. Conclusion: Selective hepatic artery infusion chemotherapy chemoembolization can be used as a routine treatment of advanced liver cancer.